NewGenIVF Highlights K25.ai Valuation Boost and Share Issuance in Balance-Sheet Update

The latest announcement is out from NewGenIvf Group ( (NIVF) ).

NewGenIVF Group Limited, a technology-driven diversified growth company spanning real estate, digital assets and reproductive health, reported net profit attributable to shareholders of US$9.9 million and net assets of about US$25.98 million for the year ended Dec. 31, 2025. The group continues to leverage its multi-segment structure and legacy IVF operations in Asia as it builds out property, DeFi and wellness-focused business lines.

On July 30, 2026, NewGen provided an update on its strategic investment in K25.ai, noting that its agreed 13% stake is now valued at roughly US$26 million based on the startup’s latest US$200 million Series A valuation, implying an expected unrealized gain of about US$8.5 million and a significant enhancement to NewGen’s balance sheet. The company also highlighted that, following the completion of a recently announced issuance of 2.5 million Class A ordinary shares, its total outstanding share count is expected to reach about 5.9 million, supporting a larger market capitalization and reinforcing its financial position as it pursues growth.

Management, led by founder, chairman and CEO Alfred Siu, framed the improved valuation of K25.ai as validation of NewGen’s investment strategy and a contributor to balance-sheet strength. The combination of 2025 profitability, asset growth and the anticipated share issuance suggests NewGen is seeking to consolidate its capital base while maintaining exposure to high-growth technology assets, a move that could influence investor perceptions of its risk profile and future expansion plans.